The study, published in the journal Advanced Science, centers on a class of compounds known as luminescent organic radicals. Unlike most fluorescent molecules, which contain paired electrons in their ground state, radicals carry unpaired electrons. That unpaired electron gives them two remarkable properties at once. It allows them to emit light through a mechanism that differs from conventional fluorescence, and it makes them paramagnetic, meaning they can accelerate the relaxation of nearby hydrogen nuclei, the very property that MRI contrast agents exploit to brighten images. In principle, a single radical molecule could therefore serve both imaging modalities, something that conventional fluorescent dyes and gadolinium-based contrast agents cannot do on their own.

The challenge, as Associate Professor Ken Albrecht of Kyushu University’s Institute for Materials Chemistry and Engineering, who led the study, explains, is that the two technologies operate on fundamentally different principles. In fluorescence imaging, a molecule absorbs photons at one wavelength and re-emits them at another, and the detector captures that emitted light. MRI, meanwhile, works by detecting the nuclear spin of hydrogen atoms in the water molecules that make up most of the body’s soft tissue. A contrast agent improves the clarity of the resulting image by altering how quickly those spins relax back to equilibrium after being excited by the scanner’s radiofrequency pulses. Designing one molecule that satisfies both sets of requirements, and does so safely in a watery biological environment, has proven extraordinarily difficult.

The Kyushu-led team began with a luminescent organic radical called tris(2,4,6-trichlorophenyl) methyl, abbreviated TTM. This trityl-type radical had already shown promise in earlier work, producing fluorescence and exhibiting the paramagnetic behavior needed for MRI contrast. But there was a critical obstacle: TTM and its early derivatives were hydrophobic, meaning they repel water. In the aqueous environment of blood, cells, and interstitial fluid, hydrophobic molecules tend to clump together, lose their optical properties, and become difficult or impossible to deliver safely. For any radical-based probe to be useful in biological systems, water solubility was non-negotiable.

The path to solubility was not straightforward. The researchers’ first generation of modified molecules achieved good MRI activity but suffered from extremely weak fluorescence, a disappointing trade-off that threatened to undo the whole point of a dual-modal probe. Through iterative chemical optimization, the team systematically adjusted the molecular architecture, tuning the balance between the radical core that governs spin behavior and the substituents that govern light emission and solubility. The result of this refinement campaign was a pair of new compounds, designated TTM-trisTP3B and TTM-trisTP9B, in which the central radical is bound in three directions to water-soluble groups, shielding the hydrophobic core while preserving its electronic properties.

Both new molecules produced deep-red fluorescence in water, a region of the spectrum that is particularly valuable for biological imaging because longer wavelengths scatter less in tissue and are less likely to be masked by the autofluorescence that biological molecules naturally emit. Deep-red and near-infrared light therefore offers a better balance of penetration depth and signal clarity than the blue and green light emitted by many conventional dyes. The fact that these radicals achieve such emission while remaining fully water-soluble marks a meaningful advance over earlier hydrophobic generations of the TTM scaffold.

The performance of the new compounds in MRI tests was equally striking. When the researchers evaluated them in phantom images, the standard laboratory test beds used to characterize contrast agents before any biological application, both molecules enhanced image contrast approximately 2.5 to 4.5 times more strongly than previously reported water-soluble TTM radicals. That improvement matters because contrast enhancement is the measure by which MRI agents are judged: a stronger effect means a lower dose can be used, reducing both cost and any potential biological burden. It also suggests that the chemical modifications did not compromise the unpaired electron’s ability to interact with nearby water protons, the essential mechanism of radical-based MRI contrast.

To probe biological compatibility, the team tested TTM-trisTP3B in living cells. The molecule was confirmed to emit fluorescence around the cell nucleus, indicating that it enters cells and distributes within them rather than being excluded or immediately degraded. Encouragingly, the fluorescence persisted for at least 24 hours, a stability that would allow long-term tracking of cells in experiments. Sustained signal is a practical prerequisite for many applications, from following transplanted stem cells to monitoring the migration of immune cells, and many fluorescent probes fade far more quickly under the continuous illumination and metabolic stress of live-cell imaging.

Perhaps the most consequential aspect of the work is what the new probes do not contain. Conventional MRI contrast agents rely on paramagnetic metals, most commonly gadolinium, a heavy lanthanide element that is highly toxic in its free form and must be tightly chelated to be safe. Concerns about gadolinium retention in the brain and other tissues, along with rare but serious reactions in patients with kidney impairment, have driven a sustained search for alternatives. A metal-free contrast agent built entirely from organic elements sidesteps those concerns at the molecular level, offering the prospect of safer, less toxic imaging agents. Because the same molecule also fluoresces, a single injection could in principle serve both a whole-body MRI scan and a high-resolution fluorescence examination, a genuinely dual-modal capability.

The researchers caution that the full utility of these molecules remains to be established. Animal studies will be needed to assess how the compounds behave in a living organism, including their circulation time, biodistribution, clearance, and long-term toxicity, before any clinical relevance can be claimed. Nevertheless, the present results establish an important proof of concept for metal-free fluorescence and MRI dual-modal imaging, and they introduce a unifying strategy that could reshape how multimodal probes are designed. The implications may extend beyond medicine. Luminescent organic radicals have attracted growing attention in quantum information science, quantum sensing, and advanced electronic materials, fields where the same unpaired electrons that make these molecules useful contrast agents also make them sensitive probes of their environment. The Kyushu team suggests that their results may serve as a foundation for future quantum sensing technologies, meaning that a molecule born from the practical demands of medical imaging could ultimately find a second life at the frontier of quantum technology, where the ability to control and read out single electron spins is the currency of progress.

Subject of Research: Development of a water-soluble, metal-free luminescent organic radical for dual-modal fluorescence and MRI imaging

Article Title: A new metal-free and water-soluble molecule that can produce florescence and used as MRI contrast material

Article References: A new metal-free and water-soluble molecule that can produce florescence and used as MRI contrast material. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Kyushu University, organic radicals, TTM, fluorescence imaging, MRI contrast agent, water-soluble molecule, dual-modal imaging, metal-free probe, bioimaging, gadolinium alternatives, Advanced Science, trityl radical

The core problem the researchers set out to solve is a tension at the heart of contrast agent chemistry. In T1-weighted MRI, contrast agents work by shortening the longitudinal relaxation time of nearby water protons, causing tissue to appear brighter on the image. The efficiency of that process is captured by a number called the longitudinal relaxivity, or r1, measured in units of inverse millimolar seconds. A higher r1 means each unit of gadolinium brightens tissue more strongly, allowing lower doses. But gadolinium-based particles can also shorten the transverse relaxation time, quantified as r2, which darkens tissue and muddies T1-weighted images when the ratio of r2 to r1 climbs too high. The ideal T1 agent would have a high r1 paired with an r2/r1 ratio as close to one as possible, meaning the particle boosts brightness without any unwanted darkening effect.

To reach that ideal, the team, led by Hui Liao and Jie Fang of Zhejiang Ocean University together with collaborators at Guangzhou First People’s Hospital, the Zhoushan Center for Disease Control and Prevention, and Suzhou Ultra-Nano Technology, turned to surface ligand engineering. Rather than redesigning the nanoparticle core itself, they focused on the shell of molecules that coats it and controls how water molecules interact with the gadolinium ions at the particle surface. Using a two-step ligand exchange strategy, the researchers synthesized ultrasmall gadolinium oxide nanoparticles and progressively swapped their surface chemistry for citrate groups. The approach reflects a growing recognition in the field that the coating on a nanoparticle is not a passive stabilizer but an active determinant of magnetic performance, governing how quickly water protons can approach, bind, and relax near the particle surface.

The results are striking on paper. At a clinically relevant magnetic field strength of 3.0 tesla, the citrate-coated gadolinium oxide nanoparticles, abbreviated Gd2O3-Cit, exhibited a longitudinal relaxivity of 8.714 per millimolar per second, approximately 2.3 times higher than Magnevist, one of the most widely used gadolinium chelates in hospitals worldwide. Just as important, the transverse-to-longitudinal ratio came in at just 1.06, nearly at the theoretical optimum of unity and among the lowest values reported to date for any gadolinium oxide based T1 contrast agent. In practical terms, that means the particles act almost purely as brightening agents, sharpening anatomical detail on T1-weighted scans without the signal loss and contrast confusion that plague many nanoparticle formulations whose r2 contributions contaminate the image.

The physics behind this performance is worth unpacking. Gadolinium ions owe their contrast power to seven unpaired electrons, which create strong local magnetic field fluctuations that accelerate the relaxation of nearby water protons. In conventional chelates, a single gadolinium ion is wrapped in an organic cage, and only a limited number of water molecules can get close enough to feel that influence. In a nanoparticle, hundreds or thousands of gadolinium ions sit at or near the surface, multiplying the number of water molecules that can be relaxed simultaneously. But that advantage comes with a catch: the same dense magnetic material can also generate strong static field inhomogeneities that dephase proton spins and drive T2 shortening, darkening the image. The ultrasmall size of the citrate-coated particles, combined with the way citrate ligands organize water access to the surface, appears to suppress that dephasing pathway almost entirely, preserving the pure T1 character of the signal.

Size matters for another reason that goes beyond magnetism: clearance. Particles small enough, typically below roughly five to eight nanometers in hydrodynamic diameter, can pass through the glomerular filtration barrier of the kidney and be excreted in urine, rather than being captured by the liver and spleen’s scavenging cells, where larger nanoparticles can accumulate for weeks or months. The researchers demonstrated that their Gd2O3-Cit particles have a plasma elimination half-life of 113.8 minutes, long enough to circulate and produce strong vascular enhancement in the liver on in vivo T1-weighted MRI, yet short enough to suggest efficient renal excretion afterward. That balance between circulation time and clearance is notoriously difficult to strike, and it is one of the key hurdles that has kept many promising nanoparticle contrast agents stuck at the preclinical stage.

Safety, of course, is the elephant in the room for anything containing gadolinium. Free gadolinium ions are toxic, interfering with calcium channels and a range of enzymes, which is why all clinical agents wrap the metal in chelating molecules. Concerns deepened after studies linked repeated gadolinium exposure to deposits in brain tissue, particularly with the older linear chelates, prompting regulatory warnings and a shift toward macrocyclic agents. The nanoparticle approach takes a different tack: instead of chelating individual ions, it locks gadolinium into a robust oxide lattice, from which release is expected to be far slower. The team reports preliminary biocompatibility data including cytotoxicity assays, hemolysis testing, and short-term histological examination, all of which indicated acceptable safety profiles under the conditions tested. The authors are careful to frame these as preliminary findings, and much longer-term biodistribution and degradation studies would be needed before any clinical translation, but the early signals are encouraging.

The work also fits into a broader renaissance in contrast agent design. Over the past decade, researchers have explored gadolinium oxide nanoparticles coated with polymers such as polyaspartic acid and poly(methyl vinyl ether-alt-maleic acid), albumin-shelled formulations for high-resolution angiography, biofabricated gadolinium oxide encapsulated in exosomes for renal clearance, and even kilogram-scale syntheses aimed at making the materials practical to produce. Others have pursued gadolinium-free alternatives, including ultrasmall iron oxide and carbon-coated ferrite nanoparticles, to sidestep gadolinium toxicity altogether. What distinguishes the new study is its focus on a single, tunable variable, the surface ligand, and its demonstration that a simple citrate coating, chosen for its biocompatibility and strong binding to gadolinium oxide surfaces, can push relaxivity and r2/r1 performance simultaneously toward the theoretical optimum without exotic chemistry.

The implications, if the approach survives further testing, could be substantial. A contrast agent with more than double the per-gadolinium efficiency of current clinical agents would allow lower injected doses, reducing both cost and any residual safety concerns. Renal clearance would spare patients the long-term organ accumulation associated with larger particles, and the strong vascular enhancement observed in the liver suggests applications in angiography, tumor imaging, and perfusion studies. The researchers also note that a pending Chinese patent application related to the work signals commercial interest in the platform. For now, the study stands as a clean proof of concept that sometimes the most powerful way to improve a nanomaterial is not to rebuild its core but to rethink what sits on its surface, one citrate molecule at a time.

Subject of Research: Development of citrate-coated ultrasmall gadolinium oxide nanoparticles as biocompatible T1-weighted MRI contrast agents with renal clearance

Article Title: Ultra-small biocompatible Gd2O3-Cit nanoparticles for improved T1-weighted MR imaging and renal clearance

Article References: Ultra-small biocompatible Gd2O3-Cit nanoparticles for improved T1-weighted MR imaging and renal clearance. (n.d.). https://doi.org/10.1007/s11051-026-06762-3

Image Credits: AI Generated

DOI: 10.1007/s11051-026-06762-3

Keywords: gadolinium oxide nanoparticles, MRI contrast agent, T1-weighted imaging, citrate coating, surface ligand engineering, relaxivity, renal clearance, biocompatibility, nanomedicine, Magnevist, ligand exchange, diagnostic imaging